Astellas Pharma Inc., a pharmaceutical company dedicated to improving the health of people around the world, has reported positive topline data from the isavuconazole phase III invasive aspergillosis study (SECURE). The antifungal agent isavuconazole is being co-developed with Basilea Pharmaceutica Ltd.
The randomized, double-blind isavuconazole study (SECURE) achieved its primary objective in demonstrating non-inferiority versus voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus species or certain other filamentous fungi. Isavuconazole was effective as determined by the primary endpoint of all-cause mortality through day 42 in the intent-to-treat population (N=516). The all-cause-mortality was 18.6 per cent in the isavuconazole treatment group and 20.2 per cent in the voriconazole group. The 95 per cent confidence interval of the treatment difference between isavuconazole and voriconazole was within the pre-specified non-inferiority margin of 10 per cent.
In addition, the key secondary endpoint of overall success rate (composite of clinical, mycological, radiological responses) at the end-of-therapy in patients with proven/ probable disease was similar between isavuconazole and voriconazole (35.0 per cent and 36.4 per cent, respectively). This outcome was based on a blinded assessment by the Independent Data Review Committee.
Overall, drug- and non-drug-related adverse events were reported in 96.1 per cent and 98.5 per cent of patients in the isavuconazole and voriconazole treatment groups, respectively. The most frequent adverse events reported were nausea, vomiting, pyrexia (fever), diarrhoea, and hypokalaemia (deficiency of potassium in the blood), which were reported at similar rates in both treatment groups. Study drug-related adverse events were reported in 42.4 per cent and 59.8 per cent of patients in the isavuconazole and voriconazole treatment groups, respectively.
“We are pleased to report these topline results from the isavuconazole SECURE study, the largest interventional study conducted in patients with invasive aspergillosis. These data provide important information on patients with this life-threatening disease as we evaluate isavuconazole as a potential therapeutic agent,” said Bernie Zeiher, senior vice president and global therapeutic area head of Immunology and Infectious Diseases at Astellas Pharma Global Development, Inc.
Enrollment in the open-label phase III isavuconazole study (VITAL) including patients with invasive fungal disease caused by mucormycetes and other emerging fungal pathogens and patients with aspergillosis and pre-existing renal impairment has been completed (N=150). Based on the investigator reported data, approximately 45 patients were enrolled with mucormycosis and a similar number of patients were enrolled with pre-existing renal impairment. Review of diagnosis and outcomes by an Independent Data Review Committee is ongoing.
Enrollment in the randomized, double-blind phase III isavuconazole study (ACTIVE), evaluating the use of isavuconazole i.v. and oral versus caspofungin i.v. followed by oral voriconazole for the treatment of invasive Candida infections, is continuing.
Isavuconazole is an investigational once daily intravenous and oral broad-spectrum antifungal for the potential treatment of severe invasive and life-threatening fungal infections. It is currently in phase III of clinical development. Isavuconazole demonstrated in-vitro and in-vivo coverage of a broad range of yeasts (such as Candida species) and molds (such as Aspergillus species) as well as in-vitro activity against emerging and often fatal molds including those that cause mucormycosis.
Isavuconazole received US FDA fast-track and US orphan drug designation for invasive aspergillosis. The phase III programme with isavuconazole includes three studies, SECURE, VITAL and ACTIVE.
The SECURE study is a global double-blind randomized phase III study, designed to evaluate the safety and efficacy of once-daily isavuconazole versus twice-daily voriconazole in the primary treatment of invasive fungal disease caused by Aspergillus species or other filamentous fungi. The VITAL study is an open-label phase III study of isavuconazole in the treatment of aspergillosis patients with pre-existing renal impairment or patients with invasive fungal disease caused by emerging and often fatal molds, yeasts or dimorphic fungi. The ACTIVE phase III study is evaluating the safety and efficacy of intravenously (i.v.) and orally administered isavuconazole versus i.v. caspofungin followed by oral voriconazole in the treatment of invasive Candida infections.